Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Cordis Corporation |
---|---|
Information provided by: | Cordis Corporation |
ClinicalTrials.gov Identifier: | NCT00232804 |
The objective of this study is to establish the safety and efficacy of the treatment with Cypher DES in diabetic patients with documented ischemia due to stenosis (small coronary artery 2.5 -3 mm in lumen diameter, with lesion between 15 mm 30 mm in length, ) in native coronary arteries.
The objective of this study is to document that the use of Cypher DES in these diabetic patients undergoing percutaneous revascularization for stenosis is safe.
Safety will be assessed over a period of 12 months.
Condition | Intervention | Phase |
---|---|---|
Coronary Artery Disease |
Device: Bx Cypher stent |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Safety and Efficacy Registry of Bx Cypher Stent in the Revascularisation of Patients With Significant Risk of Restenosis |
Enrollment: | 639 |
Study Start Date: | June 2002 |
Study Completion Date: | February 2004 |
Arms | Assigned Interventions |
---|---|
1 | Device: Bx Cypher stent |
This is a prospective, multicenter, comparative, non randomised, open registry of 1000 patients who will be followed up to 12 months at 100 sites in France. Patients will be screened according to normal practice and in relation to the inclusion and exclusion criteria. Patients should have a documented ischemia related to the target vessel.
Procedure of stent placement should be done under existing in hospital procedural protocol and care should be taken to follow Cordis instructions as set forth in the Instructions For Use. Follow up will be done according to normal procedure and the minimum should be a telephone contact at 1, 6 and 12 months.
All data gathered during the enrollment, procedure, follow up and when specific events to the patient may occur, will be entered into the Internet CRF form, by the treating physician or a person from his staff specifically appointed to this task.
Patient enrollment is anticipated to last 8 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
France | |
Université de Lille, Hôpital cardiologique | |
Lille, France, 59037 |
Principal Investigator: | Lablanche, Prof. | Université de Lille, Hôpital cardiologique |
Study ID Numbers: | 01290402 |
Study First Received: | October 4, 2005 |
Last Updated: | October 8, 2007 |
ClinicalTrials.gov Identifier: | NCT00232804 History of Changes |
Health Authority: | France: AFSSAPS - Agence Française de Sécurité Sanitaire des Produits de Santé - French Safety Medical Agency of the Health Care products |
Arterial Occlusive Diseases Coronary Disease Heart Diseases Myocardial Ischemia |
Vascular Diseases Arteriosclerosis Ischemia Coronary Artery Disease |
Arterial Occlusive Diseases Coronary Disease Heart Diseases Myocardial Ischemia |
Vascular Diseases Cardiovascular Diseases Arteriosclerosis Coronary Artery Disease |